Chimeric Therapeutics Ltd (ASX:CHM), the only ASX clinical-stage cell therapy company, welcomes the participation of leading US centre Sarah Cannon Research Institute (SCRI) in a Phase 1B glioblastoma (GBM) multi-site trial.
A clinical trial agreement has been executed with SCRI for the CHM 1101 (CLTX CAR T) Phase 1B clinical trial at the Sarah Cannon Transplant & Cellular Therapy Program at St David’s South Austin Medical Center in Austin, Texas.
A key milestone
This is a key milestone in the advancement of Chimeric’s new Phase 1B clinical trial in patients with recurrent and/or progressive glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
In a new chapter in the development of CHM 1101, Chimeric will lead a two-part Phase 1B clinical study enrolling patients with recurrent and/or progressive GBM at multiple clinical trial sites, including St David’s South in Austin.
“We are very pleased to begin a clinical collaboration with SCRI, a leading clinical research organization that serves communities across 24 states,” Chimeric Therapeutics chief medical officer Jason Litten said.
“With the integrated oncology research network of SCRI, we believe that this collaboration will enable us to rapidly advance our clinical development plan to gain an understanding of the potential benefit of CHM 1101 in patients with glioblastoma.”
About the trial
The Chimeric-sponsored Phase 1B trial will build upon the promising early outcomes seen in the CHM 1101 Phase 1A clinical trial that is ongoing at City of Hope.
Outcomes from the initial two dose levels of the Phase 1A trial have been previously presented and demonstrated patient safety with a disease stability rate of approximately 70%.
Additional details on the CHM Phase 1B trial design and objectives will be presented at the American Society of Clinical Oncology (ASCO) annual meeting as part of the Central Nervous System Tumors section on June 3, 2023.
About CHM 1101
CHM 1101 (CLTX CAR T) is a first-in-class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma.
Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope.
CHM 1101 cells uniquely utilize chlorotoxin (CLTX), a peptide component of scorpion venom, as the tumour-targeting component of the chimeric antigen receptor (CAR).
CHM 1101 CAR T cells have been shown in preclinical models to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER-2 or IL-13.
In preclinical models, CHM 1101 cells also demonstrated potent anti-tumour activity against glioblastoma while not exhibiting any off-tumour recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile.